Matthew Hemming to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Matthew Hemming has written about Xenograft Model Antitumor Assays.
Connection Strength
0.378
-
Sicinska E, Kola VSR, Kerfoot JA, Taddei ML, Al-Ibraheemi A, Hsieh YH, Church AJ, Landesman-Bollag E, Landesman Y, Hemming ML. ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs. Cancer Res. 2024 Jul 15; 84(14):2247-2264.
Score: 0.225
-
Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res. 2019 03 01; 79(5):994-1009.
Score: 0.153